Best SSRI for Panic Attacks
For panic disorder, paroxetine and sertraline are the most strongly supported SSRIs, with paroxetine demonstrating the highest efficacy and retention rates in head-to-head comparisons, though sertraline offers a favorable balance of efficacy and tolerability. 1, 2
Primary Recommendation
Among SSRIs specifically studied for panic disorder, paroxetine ranks highest for efficacy in network meta-analysis, showing strong effect sizes for response, remission, and panic symptom reduction 1. In a 12-month naturalistic comparison study, paroxetine achieved the highest retention rate (76%) compared to citalopram (68%), fluvoxamine (60%), and fluoxetine (50%) 2.
However, the choice between paroxetine and sertraline depends on tolerability priorities:
- Paroxetine: Superior early response (weeks 4-8), highest retention, but associated with more sexual dysfunction and weight gain at 12 months 2, 3
- Sertraline: Significant efficacy across all panic measures, better long-term tolerability profile, lower discontinuation syndrome risk 4
Evidence Hierarchy
The 2023 Cochrane network meta-analysis 1 provides the highest quality evidence, analyzing 70 RCTs with over 12,000 patients. Key findings:
For response rates:
- Paroxetine, fluoxetine, and venlafaxine showed strongest effects versus placebo
- Paroxetine ranked among top SSRIs for both response and remission
For tolerability (dropout rates):
- All SSRIs showed similar or better tolerability than placebo
- Sertraline demonstrated particularly favorable dropout profile
Clinical Implementation Algorithm
Start with:
- Paroxetine 10-20 mg daily if rapid response is priority and patient accepts higher risk of sexual side effects
- Sertraline 25-50 mg daily if long-term tolerability and lower discontinuation syndrome risk are priorities
Titration approach 5:
- Increase every 1-2 weeks for shorter half-life agents (sertraline)
- Start with subtherapeutic "test dose" to minimize initial anxiety activation
- Target clinical improvement by week 6, maximal response by week 12
Alternative SSRIs:
- Fluoxetine: Third-line choice; longer half-life reduces discontinuation syndrome but slower titration needed 2
- Fluvoxamine: Lowest sexual dysfunction and weight gain in completers, but highest early dropout rate (40%) 2
- Citalopram/Escitalopram: Fewer drug interactions via CYP450, but QT prolongation risk with citalopram >40mg daily 5
Critical Safety Considerations
All SSRIs carry:
- Black box warning for suicidal ideation (ages ≤24): NNH = 143 vs NNT = 3 for response 5
- Behavioral activation risk (higher in younger patients, first month of treatment) 5
- Discontinuation syndrome: Paroxetine > fluvoxamine > sertraline 5
Paroxetine-specific concerns:
- Associated with increased suicidal thinking versus other SSRIs 5
- Highest discontinuation syndrome risk—requires slow taper 5
Drug interactions to avoid:
- MAOIs (contraindicated—serotonin syndrome risk)
- Paroxetine/fluoxetine/sertraline: CYP2D6 interactions
- Fluvoxamine: extensive CYP interactions (1A2, 2C19, 2C9, 3A4) 5
Class-Level Evidence
Recent guidelines 6 and network meta-analysis 1 confirm SSRIs as first-line treatment alongside CBT. When comparing medication classes for panic disorder, SSRIs rank similarly to TCAs and benzodiazepines for efficacy, but with superior long-term safety profile. Benzodiazepines show faster onset but dependency concerns preclude first-line use 1, 6.
Combination therapy (SSRI + CBT) demonstrates superior outcomes versus monotherapy for response and remission, particularly with sertraline 5.